AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22269862
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell modulators such as belimumab and abatacept
Trial: 22270330
Drug: GM-CSF (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (500 ug daily for 4 days starting 24 hours after each chemotherapy cycle)
Trial: 22271896
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and anti-CD20 monoclonal antibody (rituximab and Iodine I-131 tositumomab)
Trial: 22272248
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid (three infusions per week)
Trial: 22272248
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of gemcitabine and erlotinib
Trial: 22273029
Drug: DTaP-IPV//PRP~T vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV//PRP~T vaccine booster
Trial: 22274724
Drug: Primary control
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary control coping (e.g., problem solving)
Trial: 22274724
Drug: Secondary control
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary control coping (e.g., acceptance)
Trial: 22277685
Drug: Elevated cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated cardiac troponin T (cTnT) ≥0.01 ng/mL
Trial: 22280813
Drug: DHEA (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (200mg daily orally for 3 months)
Trial: 22281831
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine (5 × 10^7 plaque-forming units)
Trial: 22282683
Drug: G+GM
RxNorm normalized name: Gentamicin + Glycopeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+GM
Trial: 22282683
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and G+GM
Trial: 22284809
Drug: Silencing TGF-β1
RxNorm normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silencing TGF-β1 receptors
Trial: 22284935
Drug: D-dimer threshold
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer threshold < 1000 ng mL(-1) with RGS ≤ 6
Trial: 22284935
Drug: D-dimer threshold
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer threshold < 500 ng mL(-1) with RGS ≤ 6
Trial: 22285963
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg twice daily) for 9 months
Trial: 22289660
Drug: Intra-arterial administration
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs) (100-400 × 10(6) cells)
Trial: 22289660
Drug: Intra-arterial administration
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of autologous bone marrow-derived mononuclear cells (BMMNCs)
Trial: 22289724
Drug: Oxymetazoline 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline 25 μg, 50 μg, 100 μg, and 200 μg
Trial: 22289893
Drug: Costimulated tumor-derived
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costimulated tumor-derived donor lymphocyte (TDL) infusion
Trial: 22291490
Drug: ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (5 mg/daily)
Trial: 22291490
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/daily)
Trial: 22293175
Drug: PPARγ agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPARγ agonists
Trial: 22293660
Drug: Selumetinib (AZD6244)
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib (AZD6244) 75 mg twice daily
Trial: 22294344
Drug: Anakinra 1-5
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 1-5 mg/kg/day for at least 36 months
Trial: 22298167
Drug: Intravenous dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dobutamine infused to achieve 80% of the maximum heart rate response for age
Trial: 22298944
Drug: RebiSmart™ electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RebiSmart™ electronic auto-injector for subcutaneous IFN β-1a
Trial: 22298950
Drug: Glycopyrrolate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (1 mg/5 mL), 0.02-0.1 mg/kg three times a day; n = 20
Trial: 22300696
Drug: Antiarrhythmic medication
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic medication
Trial: 22302349
Drug: Erlotinib 100
RxNorm normalized name: erlotinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 100 mg daily, gemcitabine 1,000 mg/m2, cisplatin 25 mg/m2 administered on days 1 and 8 every 3 weeks.
Trial: 22302662
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) levels >0.21 ng/mL without antibiotic treatment
Trial: 22302662
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) levels <0.05 ng/mL without antibiotic treatment
Trial: 22302662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physician estimates and PCT values
Trial: 22305344
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) with implants; no specific dosage or duration mentioned.
Trial: 22305344
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) with IPG replacement; no specific dosage or duration mentioned.
Trial: 22306782
Drug: valsartan 80-160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80-160 mg
Trial: 22308041
Drug: hyperinsulinemic-euglycemic plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperinsulinemic-euglycemic plus intralipid and heparin
Trial: 22308041
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion (SAL)
Trial: 22308240
Drug: Daily electrocardiographic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily electrocardiographic assessments
Trial: 22308288
Drug: CD20-specific CAR
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD20-specific CAR T-cell infusion after cyclophosphamide lymphodepletion
Trial: 22308288
Drug: CD20-specific CAR
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD20-specific CAR T-cell infusion
Trial: 22308295
Drug: plerixafor 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plerixafor 0.24 mg/kg/d in combination with mitoxantrone, etoposide, and cytarabine
Trial: 22315486
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg for 28 days (one cycle) for a total of six cycles or until disease progression
Trial: 22316567
Drug: All medication
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All medication groups
Trial: 22317913
Drug: Cionni-modified capsule
RxNorm normalized name: cyclosporine, modified Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cionni-modified capsule tension ring (CTR) implantation with in-the-bag single-piece AcrySof intraocular lens (IOL) implantation
Trial: 22323416
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral antidiabetes drugs (OADs)
Trial: 22325452
Drug: dHER2 combined
RxNorm normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dHER2 combined with lapatinib (1250 mg/day)
Trial: 22326470
Drug: TMC435 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 monotherapy (200mg once daily for 7 days)
Trial: 22326470
Drug: TMC435 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 monotherapy (200mg once daily for 7 days) followed by PegIFN/RBV
Trial: 22326922
Drug: GVAX combined
RxNorm normalized name: GVAX
DrugBank: GVAX (DB17276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVAX combined with 3·0 mg/kg ipilimumab
Trial: 22326924
Drug: Ipilimumab (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1, 3, 5, and 10 mg/kg) in combination with PSA-Tricom vaccine (2×10^8 plaque-forming units on day 1, followed by 1×10^9 plaque-forming units monthly)
Trial: 22326924
Drug: Ipilimumab and
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab and PSA-Tricom vaccine
Trial: 22327873
Drug: Antecedent antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent antihistamine use
Trial: 22327873
Drug: Vancomycin dose
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin dose ≥ 10 mg/kg
Trial: 22327873
Drug: Vancomycin concentration
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin concentration ≥ 5 mg/mL
Trial: 22329763
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCPs) - monophasic OCP (20 μg ethinyl estradiol plus 75 μg gestodene), 21/28 days per cycle, during 6 months
Trial: 22329763
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (OCPs) with spironolactone 100 mg for 32 patients with severe hirsutism
Trial: 22330017
Drug: PRO (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (40 g of intrinsically [1-C]phenylalanine-labeled casein protein)
Trial: 22333218
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg twice daily for the first month, then up-titrated to 125 mg twice daily.
Trial: 22335424
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (1.8 mg/m2) plus rituximab (375 mg/m2)
Trial: 22340331
Drug: Pressure-driven lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressure-driven lidocaine spray (2% lidocaine) with 10 L/min oxygen flow
Trial: 22340437
Drug: Endovascular thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombolysis (local application of rt-plasminogen activator or urokinase, mechanical thrombosuction, or a combination of both) with heparin before and after the procedure.
Trial: 22340437
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (therapeutic doses of heparin).
Trial: 22342057
Drug: Intrasphincteric autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasphincteric autologous myoblast injections followed by electrical stimulation (ES)
Trial: 22351714
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of fructose in hypercaloric trials (+104 to 250 g/d, +18% to 97% of total daily energy intake)
Trial: 22352764
Drug: NP101 transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP101 transdermal sumatriptan patch
Trial: 22353806
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin (LD) 40 mg m(-2) plus cisplatin 60 mg m(-2) every 21 days
Trial: 22354139
Drug: Basic Activities
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic Activities of Daily Living (BADL)
Trial: 22354206
Drug: DVD-R regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVD-R regimen (pegylated liposomal doxorubicin 4.0 mg/m(2), bortezomib 1.0 mg/m(2), dexamethasone 40 mg, lenalidomide 10 mg daily)
Trial: 22357361
Drug: Congestive heart
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congestive heart failure patients receiving both beta-blockers and antagonists of the renin-angiotensin-aldosterone system (n=511)
Trial: 22357361
Drug: Congestive heart
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congestive heart failure patients receiving neither renin-angiotensin-aldosterone system blockers nor beta-blockers (n=498)
Trial: 22357361
Drug: Congestive heart
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congestive heart failure patients receiving only one of the recommended classes of medications
Trial: 22357572
Drug: Active-minocycline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-minocycline plus active-aspirin
Trial: 22357572
Drug: Active-minocycline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active-minocycline plus placebo-aspirin
Trial: 22357572
Drug: Placebo-minocycline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-minocycline plus active-aspirin
Trial: 22357572
Drug: Placebo-minocycline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-minocycline plus placebo-aspirin
Trial: 22357572
Drug: Minocycline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline and aspirin
Trial: 22360915
Drug: Concurrent prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent prophylactic placement of inferior vena cava filter (CPIVCF)
Trial: 22360944
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention and stenting with different drug-eluting coatings and platforms
Trial: 22363068
Drug: Gemcitabine (675
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (675 mg/m2 i.v. over 90 minutes on days 1 and 8) in combination with docetaxel (75 mg/m2 i.v. over 1 hour on day 8) every 21 days; all patients received filgrastim or pegfilgrastim.
Trial: 22367707
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with panitumumab (gemcitabine 1000 mg/m², oxaliplatin 60 mg/m², panitumumab 6 mg/kg i.v. every 2 weeks followed by capecitabine 1000 mg/m² for 7 days)
Trial: 22371427
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg once daily (maximum-tolerated dose)
Trial: 22371427
Drug: Neratinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (various doses: 80, 160, 240, 320 mg)
Trial: 22371427
Drug: Neratinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (various doses)
Trial: 22373834
Drug: Tocilizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (10 mg/kg intravenously on Day 8)
Trial: 22373834
Drug: Methotrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10 - 25 mg orally on Days 1, 8, 15, 22, 29, 36, and 43)
Trial: 22373835
Drug: Sertraline 5
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 5 mg/d
Trial: 22373835
Drug: Sertraline 25
RxNorm normalized name: sertraline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 25 mg/d
Trial: 22373906
Drug: ANGELS of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANGELS of AF intervention (specific reports on stroke risk factors and antithrombotic therapy)
Trial: 22377126
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy (fluorouracil, epirubicin, cyclophosphamide, and bevacizumab for cycles 1-4; docetaxel, bevacizumab, and trastuzumab for cycles 5-8)
Trial: 22377126
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy
Trial: 22378328
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement, education, promotion of existing clinical services, and social support (24-week intervention)
Trial: 22381092
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% ropivacaine bilaterally into the TAP
Trial: 22381365
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with 500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene, 80 mg zinc oxide, and 2 mg cupric oxide per day for 5 days.
Trial: 22382879
Drug: linifanib 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linifanib 0.10 mg/kg
Trial: 22382879
Drug: linifanib 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linifanib 0.25 mg/kg
Trial: 22386040
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home QT interval monitoring using HeartView™ ECG recorder for 6 months
Trial: 22386040
Drug: Daily home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily home QT interval monitoring
Trial: 22388706
Drug: Sufentanil bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil bolus, starting at 0.15 μg/kg
Trial: 22393174
Drug: Bovine insulin-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine insulin-free cow's milk formula (CMF)
Trial: 22393174
Drug: Whey-based FINDIA
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey-based FINDIA formula (essentially free of bovine insulin)
Trial: 22394984
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at 1.3 mg/m(2) for normal function; 0.5 mg/m(2) for severe impairment; 0.7 mg/m(2) for moderate impairment; 1.0 mg/m(2) for mild impairment.
Trial: 22394984
Drug: Bortezomib at
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib at 0.7 mg/m(2) for moderate impairment; 0.5 mg/m(2) for severe impairment.
Trial: 22394992
Drug: MenC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC vaccine (control)
Trial: 22396585
Drug: Amlodipine or
RxNorm normalized name: amlodipine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine or Lisinopril with incident diabetes
Trial: 22397748
Drug: Repeated ultrasound-guided
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ultrasound-guided transvaginal ovarian interstitial laser treatment
Trial: 22398655
Drug: Edoxaban with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-glycoprotein (P-gp) inhibitors
Trial: 22399525
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL mangosteen juice with a high-fat breakfast
Trial: 22401488
Drug: Antidepressants (added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (added to mood stabilizers and/or atypical antipsychotics)
Trial: 22402037
Drug: PADRE-CMV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PADRE-CMV vaccine with PF03512676 adjuvant
Trial: 22402037
Drug: Tetanus-CMV vaccine
RxNorm normalized name: tetanus toxoid vaccine, inactivated
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus-CMV vaccine with PF03512676 adjuvant
Trial: 22402037
Drug: CMV peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV peptide vaccines without PF03512676 adjuvant
Trial: 22406240
Drug: Subgroup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup of MMT patients with positive urine morphine test
Trial: 22406240
Drug: Subgroup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup of MMT patients not using benzodiazepine hypnotics
Trial: 22411933
Drug: high-exposure arm
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-exposure arm (guideline-based therapy supplemented with antibiotic escalation)
Trial: 22411933
Drug: standard-exposure arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-exposure arm (guideline-based therapy)